Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06973564 · ClinicalTrials.gov registry record · Phase 1

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

A Phase 1 study of Advanced Solid Tumors, sponsored by Jacobio Pharmaceuticals Co..

Recruiting
Registry status
Phase 1
Development phase
294
Enrollment target
4
Study locations

NCT06973564 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Jacobio Pharmaceuticals Co.. The registered enrollment target is 294 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% higher). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06973564, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Jacobio Pharmaceuticals Co..

RECRUITING
Registry status
Phase 1
Development phase
294 participants
Enrollment target
4
Study locations

Study Summary

This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG JAB-23E73

Study Locations (4)

Minnesota

  • Mayo Clinic - Rochester

Missouri

  • Washington University - St Louis

Ohio

  • Cleveland Clinic Foundation - Cleveland

Utah

  • Huntsman Cancer Institute - Salt Lake City

Trial Details

FieldValue
Enrollment Target 294 participants
Start Date 2025-05-29
Est. Completion 2028-02
Phase Phase 1

Sponsor

Jacobio Pharmaceuticals Co.

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06973564

The ClinicalTrials.gov registry entry for NCT06973564 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% higher). The listed sponsor is Jacobio Pharmaceuticals Co., which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which JAB-23E73 is the first listed.

NCT06973564 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Minnesota, Missouri, Ohio.

Frequently Asked Questions

What is clinical trial NCT06973564 about?

NCT06973564 is a clinical study titled "JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration". This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors

What is the current status of trial NCT06973564?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 294 participants. The study started on 2025-05-29. Estimated completion is 2028-02.

What conditions does trial NCT06973564 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT06973564?

The interventions under investigation include: JAB-23E73 (DRUG).

Who is sponsoring clinical trial NCT06973564?

This trial is sponsored by Jacobio Pharmaceuticals Co., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06973564 being conducted?

This trial has 4 study locations across Minnesota, Missouri, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.